OUR NEW PROFILE IS: (NASDAQ: CMND)
__________
CMND trades in Canada (CSE: CMND) & Germany (FWB: CWY)
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
READ THE INVESTOR PRESENTATION HERE
_______________________
Hello Everyone,
We have another exciting profile for you for Wednesday’s session. This one operates in a unique, niche sector with a bright future ahead of it. With an uplisting in the past year to the NASDAQ, Clearmind Medicine, Inc. (NASDAQ: CMND) is a company to look at closely!
This is a perfect time to research this one.
The world is in a mental health crisis, with near all-time level highs of depression, PTSD, anxiety, and addiction. The pandemic has negatively affected many people, impacting their mental health on many levels. The current mental health treatments available, such as SSRIS for depression and rehab for addiction, may be effective, but also leave far too many people behind. Plus, the treatment for these conditions is massive, raking in billions of dollars a year, even if they aren’t effective. There needs to be a solution and the growing psychedelics movement might be it. Early scientific evidence is showing that treatments such as MDMA therapy for PTSD, psilocybin therapy for depression, and ketamine therapy for addictions, are much more effective than current treatments!
Are we looking at another sector before it goes mainstream? We all know how many millionaires were made from the MJ Sector. It is certainly worth noting that voters passed the 2020 Oregon Ballot Measure 109, making it the first state to both decriminalize psilocybin and also legalize it for therapeutic use. Colorado followed with the 2022 Colorado Ballot Measure 122.
Clearmind Medicine Inc. (Nasdaq: CMND) is a psych-e-delic pharmaceutical biotech company focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.(15)
Its primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.(15)
The Company’s intellectual portfolio currently consists of seven patent families.(15)
Clearmind Medicine Inc. (Nasdaq: CMND) intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.(15)
MAJOR CATALYSTS TO RESEARCH FOR CMND:
Groundbreaking psychedelic Medicine:
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) is a biotech company that is focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve major under-treated health problems to treat mental health disorders like depression, anxiety, and addiction. (23)
Strong Intellectual Property:
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) has a strong intellectual property portfolio, with multiple patents and patent applications covering its psych-e-delic drug candidates. On February 22, 2023, the company announced it has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psych-e-delic-based compounds.(23)
Growing Market Opportunity:
There is a massive market potential for Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND)as the company focuses on a huge untapped market with yearly economic impact costing the U.S. over $249 billion.(6)Not to mention the market for psych-e-delic medicine is growing rapidly, with the global market size projected to reach $100 billion according to Tania Gonsalves, an analyst for Canaccord Genuity Capital Markets. (24)
Robust Pipeline:
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) has a robust pipeline of psych-e-delic drug candidates in various stages of development, with a focus on developing treatments for Alcohol Use Disorder (AUD), major depressive disorder, PTSD, and addiction. (26)
First-To-Market:
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) positions to deliver a first-to-market psych-e-delic-based treatment for Alcohol Use Disorder(AUD), targeting a more than $395 million alcohol-substitute market opportunity. (27)
Experienced Leadership:
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) has—and continues to build—a culture of world-leading innovators in novel psych-e-delic treatments. Clearmind has a team of experienced leaders in the biotech and pharmaceutical industries who are focused on driving the company’s success. (25)
Strategic Partnerships:
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) has established strategic partnerships with leading academic institutions and researchers to advance its drug development programs and bring new treatments to market. (27)
Extremely Low Float:
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) has less than 6.5M shares available in its public float according to Finviz.(1) Low float stocks have the potential to present significant swings if active market participants take notice.(2)
Biotech and Pharmaceutical companies are responsible for some of the most innovative developments in the world. (10)
Biotechnology and Pharmaceutical companies must bear significant costs to develop new products and processes. Extensive research time is a key reason for these costs. However, recreating the products and processes of competitors is relatively inexpensive. (10)
Adequate patents on developments and the research that led to them help biotechnology and pharmaceutical businesses reduce the risk of copied products entering the marketplace. (10)
Intellectual Property Rights Can Be The Final Product. (10)
Not every biotechnology or pharmaceutical company sees a product through from design to manufacture. (10)
In many cases, small biotech and pharma firms license their patented innovations to larger firms with the resources capable of producing them and taking them to market. (10)
The success of these small companies depends on whether those companies can convince market participants that their firms have a sound intellectual property strategy. (10)
This strategy, which centers on patents, helps minimize the risks for those who plan to finance these types of companies. (10)
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) has a strong intellectual property portfolio, with multiple patents and patent applications covering its psych-e-delic drug candidates. (23)
On February 22, 2023, the company announced it has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psych-e-delic-based compounds. (23)
Patents Keep The Biotechnology and Pharmaceutical Industries Moving Forward (10)
Once a biotechnology or pharmaceutical firm acquires a patent, details of its technology enter the public domain. (10) The development’s description, including its advantages and claims about the product’s usage, production methods, and the product itself, are all part of the patent. (10)
Patents allow competing companies to learn what other firms are doing and be inspired to create their own innovations, in much the same way that the articles published in scientific journals inspire new research ideas and discovery efforts. (10)
Patents drive the biotechnology and pharmaceutical industry forward, which is good news for these exciting sectors and society as a whole. (10)
Patents also strengthen the biotechnology and pharmaceutical companies they protect. Firms feel encouraged to continue their research when they know they can protect the results of their efforts. These firms are also more likely to have the funds if their patented goods are a success. (10)
Patented biotech and pharmaceutical goods have the greatest value near the end of their patent period. (10)
By that time, these goods have been through clinical trials, received regulatory approval, entered the market, and hopefully gained acceptance from the public, all without any competitors. (10)
Biotech and Pharmaceutical companies are responsible for some of the most innovative developments in the world. (10)
Without the potential for patent profits, there would be no reward for innovative ideas that lead to beneficial products. (5)
These products are the technological advances that make life better.(5)
Pharmaceutical companies have the ability to develop new dr-ugs that can prolong life and provide cures to diseases that affect people worldwide.(5)
Patents are especially important to these dr-ug companies because they can guarantee profit and make all the time and cost put into developing their new dr-ug worthwhile. (5)
A patent is an economic catalyst to these pharmaceutical companies who push to research new and beneficial dr-ugs on the premise that they will be able to reap rewards by way of profits.(5)
Profits for patented pharmaceuticals represent a reward that pharmaceutical companies earn through years of research and development and only then will they be able to profit from their work. (5)
On December 21, 2022, Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND)announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute. Similar patents have already been granted to Clearmind for the MEAI-based alcohol substitute in Europe and India. (28)
The development– U.S. Patent No.11,077,072 B2 – is a major milestone for Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND), given the increasing popularity and growth in sales of non-alcoholic wine, beer and spirits. According to the information services firm NielsenIQ, the market for such non-alcoholic beverages in the U.S. in August 2022 stood at $395 million per year, showing a year-on-year growth of +20.6%. (28)
The Rise of Psych-e-delic Dr-ug Discovery in the Biotech and Pharmaceutical Industries(5)
“With psych-e-delic drugs showing promise with mental health issues, many have just begun to push into a space that could be worth up to $100 billion”, according to Tania Gonsalves, an analyst for Canaccord Genuity Capital Markets… As quoted by Psych-e-dlic Spotlight. Gonsalves added, “the companies that will emerge as the winners will have deep pockets, patentable products and a well-thought-out reimbursement strategy.” Helping, more cities are just beginning to decriminalize psychedelics, like psi-lo-cybin. (24)
For example, Denver, Oakland, and Santa Cruz have legalized the use of psi-lo-cybin. (24)
Oregon also became the first state to legalize psi-lo-cybin in a therapeutic setting. (24)
With excitement growing with psych-e-delics, one company to keep an eye on is Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND).
For decades, psych-e-delic dr-ugs like L-S-D, psil-o-cybin (magic mush-rooms), and cann-a-bis have been associated with societal outliers, hedonism, and general recklessness.(5)
But research into psy-ch-e-delics has come a long way, and biotech and pharmaceutical companies aiming to harness the therapeutic potential of psy-ch-e-delic are proliferating.(5)
The market appetite for psych-e-delics has also increased significantly over the last few years, with big money gravitating bullishly toward this flourishing sector.(5)
Despite social controversy, there is no denying that science has shown potential for psyche-del-ics to ease or even cure mental health disorders such as depression, anxiety, and trauma.(5)
Dr-ug discovery companies are also emerging that are isolating active compounds in cann-a-bis – cann-a-binoids – for therapies with better precision, bioavailability, and safety than the plant alone. (5)
And as with other progressive movements in the biopharma industry, artificial intelligence (AI) is contributing to the development of psych-e-delic therapeutics. (5)
Most psych-e-delic companies are founded with the intent to cure a mental health disorder, such as depression, anxiety, or post-traumatic stress disorder (PTSD).(5)
Clearmind Medicine Inc. (Nasdaq: CMND) is focused on the massive and relatively untapped binge behaviors and addictions market.
Alcohol Use Disorder(AUD) encompasses conditions that are referred to as alcohol abuse, alcohol dependence, alcohol addiction, and alcoholism. (19)
AUD is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. (19)
Considered a brain disorder AUD can be mild, moderate, or severe. (19)
The good news is that no matter how severe the problem may seem, evidence-based treatment with behavioral therapies, mutual-support groups, and/or medications can help people with AUD achieve and maintain recovery.(20)
According to a national survey, 14.1 million adults ages 18 and older (5.6 percent of this age group) had AUD in 2019. (20)
Among youth, an estimated 414,000 adolescents ages 12–17 (1.7 percent of this age group) had AUD during this timeframe.(20)
What Increases the Risk for AUD? A person’s risk for developing AUD depends, in part, on how much, how often, and how quickly they consume alcohol. (20)
Alcohol misuse, which includes binge drinking and heavy alcohol use, over time increases the risk of AUD.(20)
Other factors also increase the risk of AUD, such as:
- Drinking at an early age. A recent national survey found that among people ages 26 and older, those who began drinking before age 15 were more than 5 times as likely to report having AUD in the past year as those who waited until age 21 or later to begin drinking. The risk for females in this group is higher than that of males. (20)
- Genetics and family history of alcohol problems. Genetics play a role, with heritability approximately 60 percent; however, like other chronic health conditions, AUD risk is influenced by the interplay between a person’s genes and their environment. Parents’ drinking patterns may also influence the likelihood that a child will one day develop AUD.(20)
- Mental health conditions and a history of trauma. A wide range of psychiatric conditions—including depression, post-traumatic stress disorder, and attention deficit hyperactivity disorder—are comorbid with AUD and are associated with an increased risk of AUD. People with a history of childhood trauma are also vulnerable to AUD.(20)
The Solution
Breaking the Cycle Clearmind Medicine Inc. (Nasdaq: CMND) believes that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol,by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behavior.”(6)
Non-Addictive Anecdotal reports and pre-clinical in-vivo results indicate on the self-limiting property of MEAI—unlike traditional treatments.(6)
Expansive Potential The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.(6)
Successful preclinical results in MEAI treatment for alcohol consumption.(6)
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption.(6)
Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks.(6)
The groups were then given a daily dose of MEAI, with intermittent access to alcohol and water.(6)
After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving MEAI.(6)
The untreated control group showed no significant reduction in alcohol consumption.(6)
No SAEs or treatment-related histological changes were observed amongst all MEAI treatment groups compared to control naive and vehicle animals in all the examined organs.(6)
Clearmind Medicine Inc. (Nasdaq: CMND) recently announced the initiation of clinical batches of production of its novel psych-e-delic-derived dr-ug candidate.(15
Clearmind Medicine Inc. recently announced the initiation of clinical batches of production of its novel psych-e-delic-derived dr-ug candidate, the MEAI- based molecule- CMND-100.(15)
The produced batches will be used in the Company’s upcoming first in human (FIH) clinical trial evaluating the proprietary dr-ug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).(15)
Following MEAI’s synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.(15)
The clinical batches production is made possible due to prior successful production of MEAI dr-ug substance that was used in the Company’s pre- clinical studies designed to evaluate the safety of its innovative compound.(15)
“Clearmind continues its progress toward FIH clinical trials,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. (15)
“This milestone joins other achievements we’ve made in a relatively short period. Non-clinical data generated to date, demonstrate that our MEAI- based treatment has the potential to treat broad range of addictions and binge behaviors such as AUD.”(15)
“Like other addictions, AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use,” she added. (15) “Alcohol abuse is the third most-common preventable cause of death in the United States, where almost 6% struggle with this condition.”(15)
Image Source (32)
The Company previously announced that it completed a highly constructive Pre-Investigational New Dr-ug Application (“pre-IND”) meeting with the U.S. Food and Dr-ug Administration (“FDA”) to discuss the development of CMND-100.(15)
Clearmind Medicine Inc. (Nasdaq: CMND)’s Recent IPO & Nasdaq Uplisting
Clearmind Medicine Inc. (Nasdaq: CMND) was recently listed on the Nasdaq market and could be a severely undervalued company heading into 2023 with a market cap of less than $9M and its share price in the $3 – $4 range as of 12/7/22 according to MarketWatch.com. (3)
On November 14, 2022, Clearmind Medicine announced the pricing of its US $7.5 million public offering and uplisting to the Nasdaq Capital Market. (15)
Aegis Capital Corp. acted as the sole bookrunner on the offering and uplisting.(17)
Aegis Capital Corp. has been in the wealth management and investment banking business since 1984. The company is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. (17)
But Clearmind Medicine Inc. (Nasdaq: CMND) has less than 1.2M shares available in its public float according to Finviz.(1) Low float stocks have the potential to present significant swings when active market participants take notice.(2)
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) files three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psych-e-delic-based compounds. (31)
Clearmind Medicine Inc. (Nasdaq: CMND)(CSE: CMND) submitted patent applications to protect the novel compounds
Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) – SciSparc Ltd. (Nasdaq: SPRC) a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND),(FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psych-e-delic-based compounds. (31)
The patent applications refer to novel proprietary combinations of 3,4 Methyl-enedioxymeth-am-phetamine (M-D-M-A), Ibogaine and Ket-a-mine each with SciSparc’s Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™. (31)
Overall, as part of this collaboration, six other patent applications have been filed by Clearmind with the USPTO for various combinations, three of them for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of co-caine addiction and treatment of obesity and its related metabolic disorders, and recently for novel proprietary combinations of ly-sergic ac-id diethylamide (“L-S-D”), psil-o-cybin , and N,N-di-meth-yltryptamine (“D-M-T”) and SciSparc’s PEA, the active ingredient of its proprietary CannAmide™. (31)
As part of the collaboration agreement, any assets generated from the collaboration will belong to both companies.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cann-a-binoid pharmaceuticals. (31)
With this focus, the Company is currently engaged in the following drug development programs based on T-H-C and/or non-psych-o-active C-B-D: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. (31)
The Company also has a wholly-owned subsidiary whose business focuses on the sale of hemp-based products on the Amazon.com marketplace.
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc.(Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the Company and CTS Ltd. (“CTS”) have agreed to collaborate on product development.
CTS is a leading pharmaceutical and consumer products company in Israel. Founded in 1921, CTS focuses on solutions that have clinically proven efficacy and safety, supporting the health of people. In addition, CTS imports, registers, markets, and distributes healthcare products of leading global pharmaceutical companies across Israel.
As part of the collaboration, Clearmind Medicine will have access to the CTS’ state-of-the-art facilities, allowing it to expand its research and development capabilities. Furthermore, the collaboration provides Clearmind access to CTS’ global networks and industry connections, the ability to leverage CTS’ expertise in manufacturing and marketing, as well as benefit from CTS’ vast industry experience and guidance, ensuring that the Company’s treatments meet the highest standards of quality, safety, and efficacy.
“We are honored to collaborate with such a prominent pharmaceutical company. CTS’ support and expertise will be invaluable as we advance our research and development efforts in psychedelic-based therapeutics. This significant milestone recognizes Clearmind Medicine’s innovative approach as well as highlights the growing interest in the field of psychedelic-based therapies within the pharmaceutical industry. Together, we have the opportunity to revolutionize mental health treatments and provide much-needed relief to individuals suffering from a range of mental health conditions,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani.
MANAGEMENT
Adi Zuloff-Shani, PhD – CEO
Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.
Mark Haden
Previously the Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies) Canada for 10 years, Mark is an adjunct professor at the University of British Columbia School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years. Mark has provided public education on drugs and drug policy for over 30 years. Mark works with the Health Officers Council of British Columbia on their position papers on the issue of a regulated market for all currently illegal drugs. Has presented in conferences and training events in many countries. Awarded the Queen’s Diamond Jubilee Medal for drug policy reform work in 2013. Mark is the Clinical Supervisor at the Qi Integrated Health Psychedelic Assisted Therapy program.
Sara Horn, PhD
Sara has more than 30 years of experience as a clinical and regulatory affairs expert and consultant, working with regulatory bodies in the US, Europe and Israel. Her experience includes leading clinical development programs in a variety of fields within the biotech and pharmaceuticals fields, developing regulatory strategies for various products (including drug, biologics and combination products), preparation and submission of regulatory files submissions, meetings with regulatory bodies as well as planning and conducting clinical studies. Under her supervisions a list of products have been approved in both US, EU and other countries worldwide. Sarah holds a PhD in Biochemistry and Immunology.
Alan Rootenberg
Mr. Alan Rootenberg is a chartered professional accountant who has served as the Chief Financial Officer of a number of publicly traded companies, listed on the TSX, TSXV, CSE and OTCBB. Alan has a Bachelor of Commerce degree and received his CPA designation in Ontario, Canada. His extensive experience includes serving as Chief Financial Officer for mineral exploration, mining, technology and medical cannabis companies. Mr. Rootenberg holds a Certificate in the Theory of Accounting from University of Witwatersrand (1977), a bachelor’s degree in commerce from University of Witwatersrand (1975) and was registered as a CPA in 1980.
Amit Shwartz, MSc
Amit has a M.Sc. Degree in Biology from the Faculty of Life Sciences in Bar-Ilan University, Israel. He has also been published on multiple occasions. His research was done in the Neuropsychopharmacology lab, under the supervision of Professor Gal Yadid, who’s on Clearmind’s Scientific Advisory Board.
Shannon Smadella
Shannon has interviewed some of the most prominent leaders, innovators, scientists, doctors and luminaries in the psychedelic space. She was the host of Seasons 1 & 2 of ‘Examining The Psychedelic Renaissance’ with MAPS Canada. Shannon has researched, observed, coached and trained in excess of 5,000 individuals in sales, marketing, and business management and continues to help people through her company Insight Global, and enjoys interviewing leaders in the health and wellness field through her podcast ‘Dialed In’.
Yael Stav, PhD
Yael is an experienced multinational manager, with background in technology and sustainability. She has 20 years experience as a product/program/project manager in the IT and design industries, as well as the non-profit sector. Yael holds a PhD in Sustainable Design from Queensland University of Technology in Brisbane, Australia, Master of Design Management from Bezalel Academy in Jerusalem, and a Bachelor in Computer Science and Management from Tel Aviv University.
NEWS
Clearmind Medicine Announces Share-Based Payment for the Company’s Consultants
Sincerely,